Two Sigma Advisers LP increased its holdings in shares of Agenus Inc (NASDAQ:AGEN) by 56.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 719,100 shares of the biotechnology company’s stock after acquiring an additional 258,100 shares during the period. Two Sigma Advisers LP owned approximately 0.43% of Agenus worth $1,762,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Agenus by 8.5% in the fourth quarter. Geode Capital Management LLC now owns 1,509,835 shares of the biotechnology company’s stock valued at $6,144,000 after acquiring an additional 118,891 shares during the period. Chicago Equity Partners LLC lifted its stake in shares of Agenus by 61.4% in the first quarter. Chicago Equity Partners LLC now owns 157,508 shares of the biotechnology company’s stock valued at $386,000 after purchasing an additional 59,913 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Agenus by 71.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 300,910 shares of the biotechnology company’s stock worth $1,224,000 after buying an additional 125,454 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in Agenus by 272.0% during the first quarter. BNP Paribas Arbitrage SA now owns 46,783 shares of the biotechnology company’s stock worth $115,000 after buying an additional 34,208 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Agenus in the first quarter valued at about $171,000. Hedge funds and other institutional investors own 46.74% of the company’s stock.
Several brokerages recently issued reports on AGEN. ValuEngine raised Agenus from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. B. Riley reiterated a “buy” rating and issued a $6.00 price objective on shares of Agenus in a research report on Monday, June 22nd. BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a report on Thursday, June 25th. Finally, Zacks Investment Research raised shares of Agenus from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Tuesday, March 24th.
Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $15.13 million during the quarter, compared to analysts’ expectations of $12.35 million. On average, equities analysts anticipate that Agenus Inc will post -1.05 EPS for the current fiscal year.
In related news, major shareholder Corp Incyte sold 384,025 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $3.57, for a total transaction of $1,370,969.25. Following the transaction, the insider now owns 17,580,093 shares of the company’s stock, valued at $62,760,932.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 781,900 shares of company stock valued at $2,847,418. Company insiders own 4.70% of the company’s stock.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Article: Quiet Period
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.